9th Circ. Rejects Rehearing On Norvir Antitrust Deal

Law360 (August 21, 2009, 4:29 PM EDT) -- A federal appeals court has rejected a bid for an en banc rehearing of its decision to limit a settlement to $10 million in a class action alleging that Abbott Laboratories illegally jacked up the prices of its market-dominating HIV drug Norvir, sticking to its finding that the plaintiffs failed to state a claim in light of recent case law.

The U.S. Court of Appeals for the Ninth Circuit on Wednesday unanimously denied the plaintiffs' petition for rehearing. The petition for rehearing en banc was circulated to the judges of the Ninth Circuit, and no judge requested a vote for en...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!